

# Kenneth J Warrington

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1296770/publications.pdf>

Version: 2024-02-01

197  
papers

8,813  
citations

47006

47  
h-index

51608

86  
g-index

220  
all docs

220  
docs citations

220  
times ranked

6496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vacuoles, <sc>E1</sc> enzyme, Xâ€linked, autoinflammatory, somatic (<sc>VEXAS</sc>) syndrome: a presentation of two cases with dermatologic findings. International Journal of Dermatology, 2023, 62, .	1.0	8
2	Population-based Rate and Patterns of Diplopia in Giant Cell Arteritis. Neuro-Ophthalmology, 2022, 46, 75-79.	1.0	5
3	Hypothyroidism in vasculitis. Rheumatology, 2022, 61, 2942-2950.	1.9	2
4	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. Frontiers in Immunology, 2022, 13, 834981.	4.8	19
5	In Replyâ€Giant Cell Arteritis: The Place of 18F-FDG PET/CT and Serum Haptoglobin Level. Mayo Clinic Proceedings, 2022, 97, 190.	3.0	0
6	A call for uniformity in reporting patient level details during description of ophthalmologic major relapse among giant cell arteritis studies. A comment on article by Aussedat M et al. â€œEpidemiology of major relapse in giant cell arteritis: A study-level meta-analysisâ€ Autoimmunity Reviews, 2022, 21, 103062.	5.8	0
7	Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Annals of the Rheumatic Diseases, 2022, 81, 861-867.	0.9	35
8	Regulatory T Cells in Autoimmune Vasculitis. Frontiers in Immunology, 2022, 13, 844300.	4.8	10
9	Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 653-661.	0.9	49
10	Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A <sc>Pharmacogenomicsâ€Driven</sc> Machine Learning Approach. Arthritis Care and Research, 2022, 74, 879-888.	3.4	15
11	ACR and EULAR bring AAV classification into the twenty-first century. Nature Reviews Rheumatology, 2022, 18, 309-310.	8.0	2
12	Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Noninflammatory Aortic Aneurysms. Arthritis and Rheumatology, 2022, 74, 1376-1386.	5.6	4
13	Incidence, prevalence and mortality of chronic periaortitis: a population-based study.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0
14	Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritisâ€associated interstitial lung disease and idiopathic pulmonary fibrosis. FASEB Journal, 2022, 36, e22336.	0.5	27
15	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. Interactive Journal of Medical Research, 2022, 11, e27273.	1.4	2
16	Smoldering giant cell arteritis in a coronary artery. Rheumatology, 2022, 61, e384-e385.	1.9	1
17	Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. Arthritis Research and Therapy, 2022, 24, .	3.5	12
18	Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood, 2022, 140, 1496-1506.	1.4	54

#	ARTICLE	IF	CITATIONS
19	Treatment Guidelines in Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 705-724.	1.9	4
20	Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	14
21	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in <i>&lt;i&gt;ADA2&lt;/i&gt;</i> . <i>Arthritis and Rheumatology</i> , 2021, 73, 512-519.	5.6	34
22	Hospitalization Rates Are Highest in the First 5 Years of Systemic Sclerosis: Results From a Population-based Cohort (1980-2016). <i>Journal of Rheumatology</i> , 2021, 48, 877-882.	2.0	6
23	Giant cell arteritis associated with inflammatory bowel disease: a case-series and review of the literature. <i>Rheumatology International</i> , 2021, 41, 487-492.	3.0	4
24	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. <i>American Journal of Human Genetics</i> , 2021, 108, 84-99.	6.2	26
25	<sup>18</sup> F-fluorodeoxyglucose positron emission tomography/ computed tomography of giant cell arteritis with lower extremity involvement in association with polymyalgia rheumatica. <i>World Journal of Nuclear Medicine</i> , 2021, 20, 90.	0.5	0
26	NOTCH-induced rerouting of endosomal trafficking disables regulatory T cells in vasculitis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	34
27	Type II cryoglobulinemic vasculitis in the setting of MALT lymphoma. <i>BMJ Case Reports</i> , 2021, 14, e236267.	0.5	1
28	Isolated Gastrointestinal Vasculitis. <i>Rare Diseases of the Immune System</i> , 2021, , 211-223.	0.1	0
29	Increased Risk of Valvular Heart Disease in Systemic Sclerosis: An Underrecognized Cardiac Complication. <i>Journal of Rheumatology</i> , 2021, 48, 1047-1052.	2.0	9
30	Avacopan - Time to Replace Glucocorticoids?. <i>New England Journal of Medicine</i> , 2021, 384, 664-665.	27.0	6
31	Comment on: Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis: reply. <i>Rheumatology</i> , 2021, 60, e262-e263.	1.9	0
32	Prevalence of Takayasu Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2021, 48, 952-952.	2.0	11
33	Discordance Rate Among Bilateral Simultaneous and Sequential Temporal Artery Biopsies in Giant Cell Arteritis. <i>JAMA Ophthalmology</i> , 2021, 139, 406.	2.5	2
34	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	2.1	21
35	My Treatment Approach to Giant Cell Arteritis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1530-1545.	3.0	12
36	Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity. <i>Arthritis Research and Therapy</i> , 2021, 23, 164.	3.5	21

#	ARTICLE	IF	CITATIONS
37	Systemic sclerosis portends increased risk of conduction and rhythm abnormalities at diagnosis and during disease course: A US population-based cohort. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 277-285.	1.7	2
38	Pleuritis and Pericarditis in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Chest</i> , 2021, 160, 572-581.	0.8	8
39	A novel humanized model of rheumatoid arthritis associated lung disease. <i>Clinical Immunology</i> , 2021, 230, 108813.	3.2	2
40	Incidence, survival, and diagnostic trends in GCA across seven decades in a North American population-based cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1193-1199.	3.4	7
41	Gut microbial determinants of clinically important improvement in patients with rheumatoid arthritis. <i>Genome Medicine</i> , 2021, 13, 149.	8.2	41
42	Clinical Heterogeneity of the VEXAS Syndrome. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2653-2659.	3.0	58
43	Comment on: Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). <i>Rheumatology</i> , 2021, 60, e218-e219.	1.9	2
44	Classification Criteria, Epidemiology and Genetics; and Pathogenesis. <i>Rare Diseases of the Immune System</i> , 2021, , 83-92.	0.1	0
45	Application of the 3â€™ mRNA-Seq using unique molecular identifiers in highly degraded RNA derived from formalin-fixed, paraffin-embedded tissue. <i>BMC Genomics</i> , 2021, 22, 759.	2.8	3
46	VEXAS within the spectrum of rheumatologic disease. <i>Seminars in Hematology</i> , 2021, 58, 218-225.	3.4	21
47	Mitochondrial aspartate regulates TNF biogenesis and autoimmune tissue inflammation. <i>Nature Immunology</i> , 2021, 22, 1551-1562.	14.5	47
48	Histopathologic Characterization of Vexas Syndrome. <i>Blood</i> , 2021, 138, 4656-4656.	1.4	0
49	Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study. <i>Blood</i> , 2021, 138, 2608-2608.	1.4	7
50	Comment on: Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment by Naderi. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 198.	0.8	0
51	Comment on: Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment by Naderi. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 198-198.	0.8	1
52	Disease progression of Takayasu arteritis in two patients treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e21-e21.	0.9	15
53	Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes, and Adverse Events. <i>Journal of Rheumatology</i> , 2020, 47, 518-523.	2.0	13
54	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020, 59, 1118-1127.	1.9	33

#	ARTICLE	IF	CITATIONS
55	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	3.4	77
56	Morbidity and Mortality of Large-Vessel Vasculitides. <i>Current Rheumatology Reports</i> , 2020, 22, 86.	4.7	9
57	Clinical and Radiographic Features of Giant Cell Arteritis With Intracranial Involvement. <i>ACR Open Rheumatology</i> , 2020, 2, 471-477.	2.1	12
58	Effect of omega-3 fatty acids on systemic lupus erythematosus disease activity: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2020, 19, 102688.	5.8	17
59	Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2688-2704.	6.1	48
60	Beyond Giant Cell Arteritis and Takayasu's Arteritis: Secondary Large Vessel Vasculitis and Vasculitis Mimickers. <i>Current Rheumatology Reports</i> , 2020, 22, 88.	4.7	12
61	Giant cell arteritis and its mimics: A comparison of three patient cohorts. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 923-929.	3.4	10
62	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 1776-1776.	5.6	0
63	Cardiovascular Risk Factors and Atherosclerotic Cardiovascular Events Among Incident Cases of Systemic Sclerosis: Results From a Population-Based Cohort (1980-2016). <i>Mayo Clinic Proceedings</i> , 2020, 95, 1369-1378.	3.0	16
64	Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 3229-3236.	1.9	30
65	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 576-581.	3.4	25
66	Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 79-83.	0.8	1
67	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 707-713.	3.4	43
68	Clinical Characteristics of Biopsy-Proven IgA Vasculitis in Children and Adults: A Retrospective Cohort Study. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1769-1780.	3.0	26
69	Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study. <i>Journal of Rheumatology</i> , 2019, 46, 501-508.	2.0	30
70	Reply. <i>Arthritis and Rheumatology</i> , 2019, 71, 1769-1770.	5.6	0
71	The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 1545-1552.	5.6	172
72	Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature. <i>Autoimmunity Reviews</i> , 2019, 18, 399-405.	5.8	17

#	ARTICLE	IF	CITATIONS
73	Isolated Thoracic Aortic Takayasu Arteritis Presenting as Presumed Mobile Aortic Thrombus. <i>Vascular and Endovascular Surgery</i> , 2019, 53, 267-270.	0.7	3
74	Occurrence and aetiology of gastrointestinal perforation in patients with vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 32-39.	0.8	2
75	Serum S100 Proteins as a Marker of Disease Activity in Large Vessel Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 393-395.	0.9	16
76	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 322-328.	1.9	28
77	Impact of Medical Therapy on Late Morbidity and Mortality After Aortic Aneurysm Repair for Aortitis. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1731-1736.	1.3	1
78	Prognosis and monitoring of giant cell arteritis and associated complications. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 379-388.	3.0	18
79	Large Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease?. <i>Arthritis Care and Research</i> , 2018, 70, 1406-1411.	3.4	23
80	Spectrum of Aortic Disease in the Giant Cell Arteritis Population. <i>American Journal of Cardiology</i> , 2018, 121, 501-508.	1.6	25
81	Large-vessel giant cell arteritis: diagnosis, monitoring and management. <i>Rheumatology</i> , 2018, 57, ii32-ii42.	1.9	136
82	Arterial involvement in Erdheim-Chester disease. <i>Medicine (United States)</i> , 2018, 97, e13452.	1.0	24
83	Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. <i>Journal of Rheumatology</i> , 2018, 45, 1289-1295.	2.0	49
84	Smoking as a risk factor for giant cell arteritis: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 529-537.	3.4	18
85	Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. <i>RMD Open</i> , 2018, 4, e000598.	3.8	155
86	Cardiopulmonary involvement in Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 46-50.	0.8	3
87	Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E970-E979.	7.1	172
88	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 846-853.	5.6	131
89	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 837-845.	5.6	271
90	Vasculitis of the mesenteric circulation. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 85-96.	2.4	9

#	ARTICLE	IF	CITATIONS
91	Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. <i>Modern Pathology</i> , 2017, 30, 788-796.	5.5	148
92	Is Routine Imaging of the Aorta Warranted in Patients With Giant Cell Arteritis?. <i>Journal of Neuro-Ophthalmology</i> , 2017, 37, 314-319.	0.8	2
93	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	6.2	78
94	Tocilizumab â€” a new frontier for GCA therapy. <i>Nature Reviews Rheumatology</i> , 2017, 13, 700-701.	8.0	0
95	Classification of large vessel vasculitis: Can we separate giant cell arteritis from Takayasu arteritis?. <i>Presse Medicale</i> , 2017, 46, e205-e213.	1.9	21
96	Assessment of the frequency of cardiovascular risk factors in patients with Takayasuâ€™s arteritis. <i>Rheumatology</i> , 2017, 56, 1939-1944.	1.9	32
97	Clinical Spectrum of Mediumâ€Sized Vessel Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 884-891.	3.4	33
98	Polymyalgia rheumatica and risk of coronary artery disease: a systematic review and meta-analysis of observational studies. <i>Rheumatology International</i> , 2017, 37, 143-149.	3.0	12
99	Pulmonary IgG4â€related disease and colon adenocarcinoma: possible paraneoplastic syndrome. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 654-656.	1.9	6
100	Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets. <i>BMC Rheumatology</i> , 2017, 1, 2.	1.6	39
101	Healthcare Use and Direct Cost of Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2017, 44, 1044-1050.	2.0	11
102	Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0149579.	2.5	18
103	Recent advances in understanding and treating vasculitis. <i>F1000Research</i> , 2016, 5, 1436.	1.6	4
104	Predictors of Dissection in Aortic Aneurysms From Giant Cell Arteritis. <i>Journal of Clinical Rheumatology</i> , 2016, 22, 184-187.	0.9	30
105	The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2016, 43, 1078-1084.	2.0	37
106	Cerebrovascular accident in patients with giant cell arteritis: A systematic review and meta-analysis of cohort studies. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 361-366.	3.4	47
107	Risk of venous thromboembolism among patients with vasculitis: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2016, 35, 2741-2747.	2.2	18
108	The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 363.	1.9	37

#	ARTICLE	IF	CITATIONS
109	Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. <i>Ophthalmology</i> , 2016, 123, 1999-2003.	5.2	97
110	Update on the Epidemiology and Treatment of Giant Cell Arteritis. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 138-152.	1.4	4
111	Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 211-217.	4.3	64
112	Retrospective Comparison of Open versus Endovascular Procedures for Takayasu Arteritis. <i>Journal of Rheumatology</i> , 2016, 43, 427-432.	2.0	48
113	Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. <i>Rheumatology</i> , 2016, 55, 347-356.	1.9	131
114	Patients with giant cell arteritis have a lower prevalence of diabetes mellitus: A systematic review and meta-analysis. <i>Modern Rheumatology</i> , 2016, 26, 410-414.	1.8	25
115	Identification of Susceptibility Loci in <i>IL6</i> , <i>RPS9</i> / <i>LILRB3</i> , and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1361-1368.	5.6	79
116	Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they?. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 724-728.	3.4	53
117	The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950-2009. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 215-218.	1.1	72
118	Coronary artery disease in giant cell arteritis: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 586-591.	3.4	44
119	Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 1213-1217.	2.0	129
120	Cardiovascular Risk and Acute Coronary Syndrome in Giant Cell Arteritis: A Population-Based Retrospective Cohort Study. <i>Arthritis Care and Research</i> , 2015, 67, 396-402.	3.4	41
121	Rheumatoid vasculitis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 63-70.	4.3	83
122	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
123	Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1072-1077.	0.9	216
124	Visual Manifestations in Giant Cell Arteritis: Trend over 5 Decades in a Population-based Cohort. <i>Journal of Rheumatology</i> , 2015, 42, 309-315.	2.0	103
125	Body mass index and the risk of giant cell arteritis--results from a prospective study. <i>Rheumatology</i> , 2015, 54, 433-440.	1.9	33
126	Large-vessel giant cell arteritis: a cohort study. <i>Rheumatology</i> , 2015, 54, 463-470.	1.9	245



#	ARTICLE	IF	CITATIONS
127	Lower body mass index is associated with a higher risk of giant cell arteritis: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2015, 3, 232.	1.7	9
128	Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2014, 6, 8-19.	2.7	21
129	Multicentric Reticulohistiocytosis Can Mimic Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 780-781.	2.0	9
130	Hospitalized Infections in Giant Cell Arteritis – A Population-based Retrospective Cohort Study. <i>Journal of Rheumatology</i> , 2014, 41, 2447-2451.	2.0	10
131	Inflammatory Abdominal Aortic Aneurysm. <i>Vascular and Endovascular Surgery</i> , 2014, 48, 65-69.	0.7	12
132	Vasculitis associated with rheumatoid arthritis: a case-control study. <i>Rheumatology</i> , 2014, 53, 890-899.	1.9	89
133	Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. <i>American Journal of Human Genetics</i> , 2013, 93, 298-305.	6.2	143
134	Diagnostic Features, Treatment, and Outcomes of Takayasu Arteritis in a US Cohort of 126 Patients. <i>Mayo Clinic Proceedings</i> , 2013, 88, 822-830.	3.0	161
135	Vasculitis: Giant Cell Arteritis. , 2013, , 211-224.		0
136	Concurrent Takayasu Arteritis With Common Variable Immunodeficiency and Moyamoya Disease. <i>Annals of Vascular Surgery</i> , 2013, 27, 240.e13-240.e18.	0.9	23
137	CT angiographic imaging characteristics of thoracic idiopathic aortitis. <i>Journal of Cardiovascular Computed Tomography</i> , 2013, 7, 297-302.	1.3	7
138	Polymyalgia rheumatica. <i>Lancet, The</i> , 2013, 381, 63-72.	13.7	120
139	Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1989-1994.	0.9	261
140	Statin Use in Giant Cell Arteritis: A Retrospective Study. <i>Journal of Rheumatology</i> , 2013, 40, 910-915.	2.0	50
141	A primer on vasculitis. <i>Minnesota Medicine</i> , 2013, 96, 36-9.	0.1	0
142	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1329-1334.	0.9	218
143	Association of Vascular Physical Examination Findings and Arteriographic Lesions in Large Vessel Vasculitis. <i>Journal of Rheumatology</i> , 2012, 39, 303-309.	2.0	51
144	Vasculitis Associated With Tumor Necrosis Factor- $\alpha$ Inhibitors. <i>Mayo Clinic Proceedings</i> , 2012, 87, 739-745.	3.0	159

#	ARTICLE	IF	CITATIONS
145	Polyarteritis Nodosa-like Vasculitis in Association with Minocycline Use: A Single-Center Case Series. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 213-221.	3.4	56
146	Aseptic meningitis in adult onset Still's disease. <i>Rheumatology International</i> , 2012, 32, 4031-4034.	3.0	26
147	Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup. <i>Arthritis Care and Research</i> , 2012, 64, 1079-1083.	3.4	76
148	A case of refractory rheumatoid pericarditis. <i>Arthritis Care and Research</i> , 2012, 64, 935-940.	3.4	3
149	Recent Advances in Diagnostic Strategies for Giant Cell Arteritis. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 138-144.	4.2	19
150	Utility of Erythrocyte Sedimentation Rate and C-Reactive Protein for the Diagnosis of Giant Cell Arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 866-871.	3.4	233
151	The Nails Give It Away. <i>Journal of the American College of Cardiology</i> , 2011, 57, 996.	2.8	1
152	Polymyalgia Rheumatica and Giant Cell Arteritis in Older Patients. <i>Drugs and Aging</i> , 2011, 28, 651-666.	2.7	37
153	Lower extremity vasculitis in polymyalgia rheumatica and giant cell arteritis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 38-42.	4.3	25
154	Vasculitis of the Gastrointestinal Tract in Chronic Periaortitis. <i>Medicine (United States)</i> , 2011, 90, 28-39.	1.0	24
155	Evaluation for Clinical Predictors of Positive Temporal Artery Biopsy in Giant Cell Arteritis. <i>Journal of Oral and Maxillofacial Surgery</i> , 2011, 69, 36-40.	1.2	19
156	<i>Pneumocystis jirovecii</i> pneumonia in giant cell arteritis: A case series. <i>Arthritis Care and Research</i> , 2011, 63, 761-765.	3.4	41
157	A 60-year-old woman with headache, confusion, and hallucinations. <i>Arthritis Care and Research</i> , 2011, 63, 1486-1494.	3.4	7
158	The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2011, 63, 633-639.	6.7	425
159	Malignancy Risk in Vasculitis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2011, 3, 55-63.	2.7	27
160	Blocking the NOTCH Pathway Inhibits Vascular Inflammation in Large-Vessel Vasculitis. <i>Circulation</i> , 2011, 123, 309-318.	1.6	130
161	Malignancy risk in patients with giant cell arteritis: A population-based cohort study. <i>Arthritis Care and Research</i> , 2010, 62, 149-154.	3.4	34
162	Cancer preceding giant cell arteritis: A case-control study. <i>Arthritis and Rheumatism</i> , 2010, 62, 1763-1769.	6.7	23

#	ARTICLE	IF	CITATIONS
163	Increase in age at onset of giant cell arteritis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 780-781.	0.9	82
164	Localized vasculitis of the gastrointestinal tract: a case series. <i>Rheumatology</i> , 2010, 49, 1326-1335.	1.9	54
165	Images in vascular medicine. <i>Vascular Medicine</i> , 2010, 15, 135-136.	1.5	3
166	Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study. <i>Rheumatology</i> , 2010, 49, 2104-2108.	1.9	14
167	Scalp necrosis in giant cell arteritis after initiation of therapeutic corticosteroids. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 343-344.	1.2	3
168	Lack of association of high body mass index with risk for developing polymyalgia rheumatica. <i>International Journal of Rheumatic Diseases</i> , 2010, 13, e1-5.	1.9	6
169	Chronic natural killer cell lymphocytosis successfully treated with alemtuzumab. <i>Blood</i> , 2009, 114, 3500-3502.	1.4	10
170	Symptomatic Lower Extremity Vasculitis in Giant Cell Arteritis: A Case Series. <i>Journal of Rheumatology</i> , 2009, 36, 2277-2283.	2.0	69
171	Noninfectious Ascending Aortitis: A Case Series of 64 Patients. <i>Journal of Rheumatology</i> , 2009, 36, 2290-2297.	2.0	83
172	Vasculitis working group: Selected unanswered questions related to giant cell arteritis and anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Joint Bone Spine</i> , 2009, 76, 440-443.	1.6	10
173	Delayed Diagnosis of Biopsy-Negative Giant Cell Arteritis Presenting as Fever of Unknown Origin. <i>Journal of General Internal Medicine</i> , 2009, 24, 532-536.	2.6	18
174	Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. <i>Arthritis Research and Therapy</i> , 2009, 11, R50.	3.5	33
175	Cardiovascular risk factors and acute-phase response in idiopathic ascending aortitis: a case control study. <i>Arthritis Research and Therapy</i> , 2009, 11, R29.	3.5	10
176	Exercise Echocardiography in Rheumatoid Arthritis: A Case-Control Study. <i>Journal of the American Society of Echocardiography</i> , 2009, 22, 1228-1231.	2.8	9
177	Personalized medicine for the vasculitis patient: hope for the future?. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 127-132.	0.3	1
178	A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. <i>Arthritis and Rheumatism</i> , 2008, 58, 1810-1822.	6.7	99
179	A 61-year-old man with livedo reticularis. <i>Arthritis and Rheumatism</i> , 2008, 59, 1682-1684.	6.7	3
180	Surgical management of ascending aortic aneurysm due to non-infectious aortitis. <i>Scandinavian Cardiovascular Journal</i> , 2008, 42, 417-424.	1.2	21

#	ARTICLE	IF	CITATIONS
181	Characterisation of the immune response to type I collagen in scleroderma. <i>Arthritis Research and Therapy</i> , 2006, 8, R136.	3.5	21
182	Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. <i>Clinical and Experimental Immunology</i> , 2006, 146, 371-380.	2.6	17
183	Modulation of TNF- $\alpha$ Gene Expression by IFN- $\gamma$ and Pamidronate in Murine Macrophages: Regulation by STAT1-Dependent Pathways. <i>Journal of Immunology</i> , 2005, 174, 1801-1810.	0.8	32
184	Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. <i>Arthritis Research and Therapy</i> , 2005, 7, R984.	3.5	124
185	Prognostic markers of radiographic progression in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 43-54.	6.7	160
186	Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2713-2715.	6.7	6
187	Anti-tumor necrosis factor $\alpha$ therapy in rheumatoid arthritis: Hitting two birds with one stone?. <i>Arthritis and Rheumatism</i> , 2004, 51, 309-310.	6.7	5
188	Concomitant giant cell aortitis, thoracic aortic aneurysm, and aortic arch syndrome: Occurrence in a patient and significance. <i>Arthritis and Rheumatism</i> , 2003, 49, 858-861.	6.7	17
189	Toward a broader understanding of aldosterone in congestive heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 155-163.	1.7	17
190	Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 285, H813-H821.	3.2	100
191	CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. <i>Blood</i> , 2003, 101, 3543-3549.	1.4	121
192	Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets. <i>Current Drug Targets</i> , 2003, 4, 505-516.	2.1	41
193	Acute myeloid leukemia associated with necrotizing temporal arteritis. <i>Journal of Rheumatology</i> , 2003, 30, 846-8.	2.0	7
194	T-Cell-Mediated Lysis of Endothelial Cells in Acute Coronary Syndromes. <i>Circulation</i> , 2002, 105, 570-575.	1.6	332
195	61-Year-Old Man With Dyspnea and Bilateral Foot Drop. <i>Mayo Clinic Proceedings</i> , 2002, 77, 363-366.	3.0	1
196	CD4+,CD28+ T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. <i>Arthritis and Rheumatism</i> , 2001, 44, 13-20.	6.7	208
197	Incidence, prevalence and mortality of chronic periaortitis: a population-based study. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	0